Compare AGM & PRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AGM | PRCT |
|---|---|---|
| Founded | 1987 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.5B |
| IPO Year | N/A | 2021 |
| Metric | AGM | PRCT |
|---|---|---|
| Price | $158.14 | $26.16 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 10 |
| Target Price | ★ $215.00 | $36.13 |
| AVG Volume (30 Days) | 104.3K | ★ 1.8M |
| Earning Date | 01-01-0001 | 05-27-2026 |
| Dividend Yield | ★ 4.02% | N/A |
| EPS Growth | N/A | ★ 1.71 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $308,054,000.00 |
| Revenue This Year | $22.27 | $32.85 |
| Revenue Next Year | $4.06 | $24.66 |
| P/E Ratio | $9.95 | ★ N/A |
| Revenue Growth | N/A | ★ 37.22 |
| 52 Week Low | $146.69 | $19.35 |
| 52 Week High | $210.64 | $64.89 |
| Indicator | AGM | PRCT |
|---|---|---|
| Relative Strength Index (RSI) | 41.83 | 43.73 |
| Support Level | $156.98 | N/A |
| Resistance Level | $168.85 | $31.04 |
| Average True Range (ATR) | 6.07 | 1.86 |
| MACD | -1.09 | -0.14 |
| Stochastic Oscillator | 35.13 | 64.27 |
Federal Agricultural Mortgage Corp provides agricultural real estate and rural housing mortgage loans in the secondary market in the U.S. Its operations consist of seven segments: Farm & Ranch, Corporate AgFinance, Power & Utilities, Broadband Infrastructure, Renewable Energy, Funding, and Investments. The company purchases eligible mortgage loans secured by first liens on agricultural real estate and rural housing under the Farm & Ranch line of business. Its subsidiary purchases portions of certain agricultural, rural development, business and industry, and community facilities loans guaranteed by the USDA.
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.